Dr. Nathanael Gray is a recognized leader in the field of chemical biology and small molecule protein kinase inhibitors and has 125 published articles and over 40 patents on this subject. Dr. Gray is an expert in the disciplines of combinatorial, medicinal chemistry, and small molecule mechanism-of-action studies. He has contributed to the development of several clinical candidates targeting oncogenic kinases, and his team was responsible for developing the drug NVP-BAF312, an agonist of the sphingosine-1-phosphate receptors that is currently in a phase III clinical study for the treatment of multiple sclerosis. Dr. Gray has contributed to the basic elucidation of new kinase inhibitory mechanisms, such as the discovery of the first allosteric inhibitors of Bcr-Abl (GNF-2/5), the discovery of the first potent inhibitors of EML4-ALK kinase (TAE684), the development of the first mutant specific inhibitors of T790M EGFR (WZ4002), and the first covalent inhibitors of JNK (JNK-IN-8). Dr. Gray’s experience in developing small molecule inhibitors both in academia and industry (Novartis) from discovery through clinical development make him exceptionally well suited to lead the medicinal chemistry efforts in Project 1 aimed at developing inhibitors of dengue virus entry. Drs. Gray, Yang and Harrison have been productively collaborating to develop inhibitors of dengue viral entry described in project 1. In addition, Dr. Gray has extensive experience in target identification strategies, having successfully identified the targets of multiple small molecule screening hits utilizing affinity chromatography and mass spectrometry and genetic techniques; this experience will be valuable for investigating the mechanism of action of Ebola virus entry inhibitors described in Project 2.